Overview

Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to demonstrate bioequivalence between insulin detemir produced by the NN729 process and by the current process in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Detemir
Insulin, Globin Zinc